Read more description (this text will be under a "Read more" link

Eligible subjects will be randomly assigned by chance to EITHER canakinumab or to a placebo (inactive substance) after completing the screening procedures. Neither you nor your study doctor will know what treatment you are getting

You will be in the study for about 4.5 months.

During the time while you are hospitalized a study doctor will see you every day up to your discharge or day 29, whichever comes first. After discharge, you will not be required to return to the hospital for the purpose of this study and will receive follow up by phone call at days 15, 29, 57 and 127 after starting the study medication. See Section 3 and Section 4 for more details.

At the study visits in the hospital, the following procedures should happen: your health status will be assessed, your oxygen level will be measured and blood will be collected, and, during phone calls, your health status and medications that you are taking will be assessed.

You will not be paid for being in this study.
Close research trial
No
Eligibility Requirements
  • Male or female
  • Adults (≥ 18 years old)
  • Body weight ≥ 40 kg
  • Hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray or CT scan
[email protected] Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID)(IRB: H-40162) H-40162

We are conducting this research study to find out if the study treatment canakinumab (also known as ACZ885) is safe and effective in helping people who have coronavirus (COVID-19) pneumonia and inflammation.